|
Syncona Ltd on Thursday noted that its portfolio company Autolus Therapeutics PLC had widened its third quarter loss as it continued to progress its candidate pipeline.
Autolus is a clinical-stage biopharmaceutical company focused on the development and commercialisation of T-cell immunotherapy products to combat cancer.
Syncona invests in healthcare companies. The London-based firm said its strategy is to "found, build and fund companies around exceptional science to create a diversified portfolio of 15 to 20 globally leading healthcare businesses."
In the third quarter of 2022, Autolus Therapeutics reported a pretax net loss of $48.9 million, widened from $39.4 million the previous year.
It reported license revenue of $2.4 million in the quarter, compared to none last year, but received no grant income, compared to $236,000 the year prior.
In the same period, research & development costs rose to $37.6 million from $32.3 million, primarily relating to the company's obecabtagene autoleucel clinical product candidate.
Syncona did not comment directly on the portfolio firm's results.
Shares in Syncona were down 0.5% at 180.13 pence on Thursday morning in London.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
